You have accessJournal of UrologyUrodynamics/Lower Urinary Tract Dysfunction/Female Pelvic Medicine: Non-neurogenic Voiding Dysfunction II (MP63)1 Sep 2021MP63-14 OUTCOMES OF ONABOTULINUMTOXIN A INJECTION INTO THE EXTERNAL URETHRAL SPHINCTER FOR VOIDING DYSFUNCTION IN FEMALES Mehwash Nadeem, Jamie Lindsay, Mahreen Pakzad, Rizwan Hamid, Jeremy Okrim, and Tamsin Greenwell Mehwash NadeemMehwash Nadeem More articles by this author , Jamie LindsayJamie Lindsay More articles by this author , Mahreen PakzadMahreen Pakzad More articles by this author , Rizwan HamidRizwan Hamid More articles by this author , Jeremy OkrimJeremy Okrim More articles by this author , and Tamsin GreenwellTamsin Greenwell More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002103.14AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Voiding dysfunction(VD) in females is a common condition with different underlying causes {(detrusor underactivity(DU), detrusor acontractility(DA) or high-tone non-relaxing sphincter(HTNRS)} and limited treatment options. In this study, we assessed the functional outcomes of onabotulinumtoxin A(Botox A) injection into the external urethral sphincter(EUS) for VD in females with non neurogenic HTNRS METHODS: A retrospective analysis of a prospectively maintained database was performed assessing all 34 women of mean age 37.6(18-72) years with HTNRS (maximal urethral closure pressure(MUCP) >92 – age in years), DU or DA receiving their first EUS Botox A injection between Jan 2015 and Nov 2019. All were evaluated with pre-operative videourodynamics(VUDS) and urethral pressure profilometry(UPP) and all received 100U Botox A. All had maximum free flow(QMax), post void residual (PVR) and PGI-I (Patient global impression of improvement) Scale measurement at 3 months post-injection. Median follow up was 18 months. RESULTS: Outcomes are detailed in the table.On multivariate analysis patients with high pre-operative MUCP (>100 cmH2O) were more likely to have improved Q Max (p=0.0054), reduction in the need to CISC (p=0.047), and reduction in PVR (p=0.006). However, MUCP value cannot predict the likelihood of subjective improvement (p-value=0.11) CONCLUSIONS: Botox A injection to the EUS in women with VD due to HTNS or DA is a valid treatment option considering therapeutic options are limited with a 70% response rate and a significant reduction in the need to CISC. However due to the short duration of benefit and the need for repeat treatments long-term continuation occurs in only 9%. Source of Funding: N/A © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e1107-e1107 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Mehwash Nadeem More articles by this author Jamie Lindsay More articles by this author Mahreen Pakzad More articles by this author Rizwan Hamid More articles by this author Jeremy Okrim More articles by this author Tamsin Greenwell More articles by this author Expand All Advertisement Loading ...